
Valiltramiprosate Demonstrates Greater Promise in Milder Forms of Alzheimer Disease, Phase 3 APOLLOE4 Study Shows
New data from the phase 3 APOLLOE4 trial (NCT04770220) of valiltramiprosate (Alzheon), a valine prodrug of tramiprsate, showed that the agent did not meet its primary end point in a larger cohort of mild Alzheimer disease (AD); however, did show more …